Dernières nouvelles pour Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Pyxis Oncology Inc

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12138033).pn<img src="https://pbs.twimg.com/media/GcNLzzIWUAA9vxq?format=jpg&amp;name=900x900" alt="Image" />

Biotech

News

General

CHEK

Check-Cap Granted US Patent #12138033 For "SYSTEM AND METHOD FOR POLYP AND COLON CANCEROUS GROWTH DETECTION THROUGH CAPSULE DYNAMICS". Also 'Uses a Neural Network to Determine a Probability Score'.

WIIM

BILL

BILL Holdings shares are trading higher on continued strength after the company last week reported better-than-expected Q1 financial results and issued FY25 guidance above estimates. Goldman Sachs maintained a Neutral rating on the stock but raised its PR from $60 to $77.

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111122024_Sorensen_EVAX.pdf</a>

EVAX

Watching Evaxion Biotech; Zacks Small-Cap Research Gives Stock $7.25 Price Valuation

In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $21.00, and a low estimate of $15.00. Observing a 3.8% increase, the current average has risen from the previous average price target of $16.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1731441719_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Amicus Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dennis Ding</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amicus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amicus Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Delving into Amicus Therapeutics's Background</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Financial Milestones: Amicus Therapeutics's Journey</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Amicus Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 36.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amicus Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.32%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Amicus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.88%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Amicus Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 2.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

FOLD

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts

ONMD

OneMedNet shares are trading higher after it announced continued investment in Bitcoin which is currently seeing record highs.

Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is expanding its search for a successor to CEO Bob Iger, considering external candidates as the company&#8217;s board, led by incoming Chairman James Gorman, aims to stabilize the succession process.
The move signals a shift from an internal competition among Disney&#8217;s top executives to a broader search, including external contenders such as Andrew Wilson, CEO of Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/media/disney-explores-wider-field-of-candidates-to-succeed-iger-d1876792" rel="noreferrer noopener">reports</a>.
According to the report, Disney has partnered with executive search firm Heidrick &amp; Struggles to evaluate potential external candidates, and at least two more contenders have been identified beyond Wilson.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution" rel="noreferrer noopener">AppLovin&#8217;s High Valuation and Expansion Beyond Gaming Prompt Analyst Caution</a>
The decision comes as Gorman, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41432091/disneys-leadership-shift-james-gorman-named-as-chairman-ceo-search-underway" rel="noreferrer noopener">set to take over</a> as Chairman in January, pushes for a comprehensive review of candidates, signaling his intent to find the right leader to guide Disney beyond Iger&#8217;s tenure.
The company has announced it plans to finalize its choice for the CEO role by early 2026, delaying its previous timeline.
Wilson, who has previously discussed potential deals with Disney and even interviewed for a senior role at ESPN in 2018, remains a strong external contender.
Recent talks have also explored partnerships between Electronic Arts and Disney&#8217;s ESPN, although these discussions have yet to materialize into a deal, the report states.
The WSJ report says that internally, Disney had four key executives vying for the CEO role: Dana Walden, Alan Bergman, Josh D&#8217;Amaro, and Jimmy Pitaro. Each company manages significant areas of Disney&#8217;s business, from streaming to theme parks.
Last week, Disney launched the <a target="_blank" href="https://www.benzinga.com/news/24/11/41720954/disney-creates-new-tech-hub-for-ai-and-ar" rel="noreferrer noopener">Office of Technology Enablement</a> to drive AI and XR innovation across media and parks.
Jim Cramer <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41432091/disneys-leadership-shift-james-gorman-named-as-chairman-ceo-search-underway" rel="noreferrer noopener">showed interest in</a> buying more Disney stock if it dips below $90, stressing the potential value of the company&#8217;s theme parks amid current challenges. Disney laid off 300 corporate employees in September, following earlier cuts of 140 staff in its TV division and 175 at Pixar this year.
The recent U.S. presidential election victory of Donald Trump has also introduced new uncertainties for Disney. Trump&#8217;s criticism of Taiwan and potential changes in trade policies could impact Disney&#8217;s strategic decisions, particularly regarding its international investments and partnerships.
Walt Disney Co stock gained over 10% year-to-date. Investors can gain exposure to the stock through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>).
Price Actions: DIS stock is down 0.23% at $100.63 at&nbsp;the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>
Image via Shutterstock

Management

Media

Who Will Succeed Disney CEO Bog Iger?

Genius Group shares are trading higher after the company announced it adopted a Bitcoin treasury reserve strategy.

Alex Fazel, Chief Partnership Officer at Swissborg, sees Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) as the "best Trump proxy", highlighting its potential to <a href="https://www.benzinga.com/general/education/24/11/41882342/heres-how-much-100-in-dogecoin-today-could-be-worth-if-doge-hits-new-all-time-highs-2#:~:text=If%20Dogecoin%20can%20return%20to,more%20%E2%80%9CMuch%20Wow%E2%80%9D%20moments.">reach one dollar</a>.
What Happened: Fazel shared his portfolio in a <a href="https://x.com/tradetheflow_/status/1856290955244253659">post</a> on X, saying that meme coins make up a small and speculative portion of his holdings, while his primary investments are Bitcoin, Solana, Ethereum and a few DeFi and AI projects.
Fazel sees Goatseus Maximus (CRYPTO: GOAT) as an "OG meme" with staying power, recently gaining a Bybit listing and potentially a Binance spot listing soon.
His other meme holdings include Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>), Toshi (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TOSHI</a>) and Peanut The Squirrel (CRYPTO: PNUT) as a rising mascot meme. Toshi and Popcat are each &#8220;backed by strong communities,&#8221; according to the expert. 
He predicted, "After a long period of consolidation, the chart also looks ready to send."
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin About To Enter The &#8216;Euphoria&#8217; Stage</a>
The expert provides insight into the meme coin market, which has seen significant growth and volatility in recent years. His tweet serves as a reminder of the potential upside in the meme coin market, despite its inherent risks and volatility.
Price Action: Dogecoin is up 20% over the past 24 hours, trading at 38 cents.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41876486/dogecoin-explodes-for-86-weekly-gain-what-is-going-on">Dogecoin Explodes For 86% Weekly Gain: What Is Going On?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$POPCAT

$TOSHI

Dogecoin Is The 'Best Trump Proxy,' Industry Expert Claims

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Legal

Movers

AMED

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

Nano Labs shares are trading higher. Yesterday the company said it will start accepting payments in Bitcoin.

MNDY

Monday.com shares are trading lower. DA Davidson and Baird maintained Neutral ratings on the stock.

Global

Trading Ideas

AAPL

'Recent Market Rumor Suggests That Apple Is Looking To Hon Hai (Foxconn) To Manufacture AI Servers' - DigiTimes Alert

<a href="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power" title="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power">https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power</a>
<a href="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power" title="https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power">https://www.axios.com/2024/11/12/biden-moves-to-boost-nuclear-power</a>

LTBR

OKLO

Reported Earlier: 'White House plan would provide huge boost for nuclear power' -Axios

Deep-pocketed investors have adopted a bearish approach towards Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FICO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Fair Isaac. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 7% leaning bullish and 53% bearish. Among these notable options, 2 are puts, totaling $67,500, and 11 are calls, amounting to $519,907.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1290.0 to $2460.0 for Fair Isaac over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Fair Isaac stands at 55.14, with a total volume reaching 17.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Fair Isaac, situated within the strike price corridor from $1290.0 to $2460.0, throughout the last 30 days.
<h3>Fair Isaac 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731440855_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1067.0</td>
<td>$1057.8</td>
<td>$1057.8</td>
<td>$1290.00</td>
<td>$105.7K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$838.5</td>
<td>$830.0</td>
<td>$830.0</td>
<td>$1550.00</td>
<td>$83.0K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$487.9</td>
<td>$478.0</td>
<td>$483.0</td>
<td>$2150.00</td>
<td>$48.3K</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$220.9</td>
<td>$213.0</td>
<td>$215.0</td>
<td>$2200.00</td>
<td>$43.0K</td>
<td align="right">30</td>
<td align="right">2</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$392.0</td>
<td>$388.2</td>
<td>$392.0</td>
<td>$2000.00</td>
<td>$39.2K</td>
<td align="right">320</td>
<td align="right">2</td>
</tr>
</tbody>
</table>

<h3>About Fair Isaac</h3>
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Having examined the options trading patterns of Fair Isaac, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Fair Isaac</h3>
<ul>
<li>Currently trading with a volume of 69,391, the FICO's price is down by 0.0%, now at $2350.0. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 72 days.</li>
</ul>
<h3>Professional Analyst Ratings for Fair Isaac</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $2252.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $2040. 
&#x2A; An analyst from Baird persists with their Neutral rating on Fair Isaac, maintaining a target price of $2000. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Fair Isaac, maintaining a target price of $2350. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Fair Isaac, maintaining a target price of $2374. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Fair Isaac, which currently sits at a price target of $2500. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Fair Isaac options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

FICO

Check Out What Whales Are Doing With FICO

Whales with a lot of money to spend have taken a noticeably bearish stance on MongoDB.
Looking at options history for MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $384,622 and 2, calls, for a total amount of $143,050.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $300.0 for MongoDB over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for MongoDB's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across MongoDB's significant trades, within a strike price range of $210.0 to $300.0, over the past month.
<h3>MongoDB 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731440849_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$48.25</td>
<td>$46.0</td>
<td>$46.0</td>
<td>$260.00</td>
<td>$115.0K</td>
<td>341</td>
<td align="right">25</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$32.35</td>
<td>$32.35</td>
<td>$300.00</td>
<td>$100.2K</td>
<td>785</td>
<td align="right">35</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.1</td>
<td>$21.05</td>
<td>$21.05</td>
<td>$270.00</td>
<td>$71.5K</td>
<td>32</td>
<td align="right">105</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.87</td>
<td>$1.24</td>
<td>$1.5</td>
<td>$280.00</td>
<td>$45.0K</td>
<td>1.7K</td>
<td align="right">303</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.2</td>
<td>$26.5</td>
<td>$27.2</td>
<td>$270.00</td>
<td>$40.8K</td>
<td>159</td>
<td align="right">21</td>
</tr>
</tbody>
</table>

<h3>About MongoDB</h3>
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Following our analysis of the options activities associated with MongoDB, we pivot to a closer look at the company's own performance.
<h3>Where Is MongoDB Standing Right Now?</h3>
<ul>
<li>With a trading volume of 610,507, the price of MDB is up by 0.83%, reaching $294.0.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MongoDB options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on MDB Options

Investors with a lot of money to spend have taken a bearish stance on Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with U, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Unity Software.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 70%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $37,635, and 9, calls, for a total amount of $664,840.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $30.0 for Unity Software, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Unity Software's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Unity Software's significant trades, within a strike price range of $10.0 to $30.0, over the past month.
<h3>Unity Software Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731440845_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.7</td>
<td>$2.5</td>
<td>$2.58</td>
<td>$30.00</td>
<td>$221.8K</td>
<td>6.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.85</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$14.00</td>
<td>$86.2K</td>
<td>770</td>
<td>151</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.72</td>
<td>$0.71</td>
<td>$0.7</td>
<td>$22.00</td>
<td>$82.6K</td>
<td>4.0K</td>
<td>1.7K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.75</td>
<td>$2.66</td>
<td>$2.66</td>
<td>$30.00</td>
<td>$79.8K</td>
<td>6.3K</td>
<td>316</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.05</td>
<td>$1.99</td>
<td>$2.05</td>
<td>$20.00</td>
<td>$61.5K</td>
<td>20.1K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
<h3>Where Is Unity Software Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,161,737, the U's price is down by -3.86%, now at $19.42. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 104 days.</li>
</ul>
<h3>What Analysts Are Saying About Unity Software</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $19.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Unity Software, targeting a price of $20. 
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $20. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Unity Software, targeting a price of $26. 
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Underperform rating for Unity Software, targeting a price of $16. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Sell rating for Unity Software, targeting a price of $15. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Unity Software options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With Unity Software

IBRX

ImmunityBio shares are trading higher after the company reported better-than-expected Q3 financial results. D.Boral maintained a Buy rating on the stock.

CGON

CG Oncology shares are trading lower. The company reported Q3 financial results.

IAC shares are trading lower following Q3 financial results.

Agilon Health shares are trading lower after Stifel cut its price target on the stock from $7 to $2.

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading... The oncology market is playing an inevitable role worldwide with its latest innovation offering solutions for fatal diseases. Also, the rapidly rising R&amp;D activities and surging investments, coupled with the adoption of cutting-edge technologies are propelling the growth and development of the market.
Given the industry's rosy prospects, it could be wise to invest in fundamentally strong biotech stocks Pyxis Oncology, Inc. (<a href="https://stocknews.com/stock/PYXS/">PYXS</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>) poised for major upside.
Incidents of patients being affected by cancer is increasing dramatically and is projected to grow through the middle of the century across the globe. Simultaneously, ecosystem engaged in the discovery, developing, and delivering breakthrough therapies in entirely new areas of science is on steep high levels.
These factors are continuously contributing to the <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024">breakthroughs in the oncology market and propelling its prospects</a>. Last year, over 25 novel oncology active substances were unveiled worldwide, and more than 2,000 new oncology clinical trials were set in motion, such as cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies.
The oncology drugs market is expected to reach a projected revenue of $194.10 billion by 2024 worldwide. In comparison to the world, the US continues its dominance over the world in the segment with <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/oncology-drugs/worldwide">oncology drug development and innovation</a>, having numerous breakthrough therapies approved by the FDA and is expected to generate the highest revenue, with $103.90 billion in 2024.
The global oncology drugs market is anticipated to reach $518.25 billion by 2032, exhibiting growth at a notable <a href="https://www.fortunebusinessinsights.com/oncology-drugs-market-103431">CAGR of 11.3%</a>. Factors including the rising prevalence of different type of cancer, increasing new drug launches and product approvals, and growing research activities in the field contribute to the market growth.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Pyxis Oncology, Inc. (<a href="https://stocknews.com/stock/PYXS/">PYXS</a>)
PYXS is a clinical stage company engaged in the development of therapeutics to treat cancers. The company's lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1, in the Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors.
On August 15, PYXS announced that its PYX-201, an ADC that uniquely targets EDB+FN within the tumor stroma which is PYXS' lead clinical program is being evaluated in an ongoing Phase 1 trial in multiple types of solid tumors. The company expects to announce preliminary data from the Phase 1 trial of PYX-201 in the fall of 2024.
For the six months that ended June 30, 2024, PYXS posted <a href="https://www.investopedia.com/terms/r/revenue.asp">total revenues</a> of $16.15 million, of which its royalty revenues stood at $8.15 million for the same period. The company's total other income, net came in at $5.08 million for the half year.
In addition, the company's cash and cash equivalents were $25.07 million as of June 30, 2024, compared to $9.6 million as of December 31, 2023.
Shares of PYXS have increased 79.7% over the past year to close the last trading session at $3.81. Wall Street analysts expect the stock to hit $8 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/pyxs/forecast">upside of 110%</a>.
PYXS' robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, PYXS is ranked #90 out of 341 stocks.
<a href="https://stocknews.com/stock/PYXS/">Click here</a> to access additional ratings of PYXS for Stability, Growth, Value, Quality, and Momentum.
Stock #2: Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Headquartered in Tübingen, Germany, IMTX is a clinical-stage biopharmaceutical company which focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities.
IMTX's revenue has grown at a CAGR of 33.3% over the past three years. The company's tangible book value has increased 72.6% over the same timeframe, while its total assets have improved at a CAGR of 42.5%.
IMTX's revenue from collaboration agreements increased 52.5% from the year-ago value to €49.02 million ($54.77 million) during the six months that ended June 30, 2024. The company's cash and cash equivalents and total assets came in at €158.14 million ($176.69 million) and €626.97 million ($700.51 million) as of June 30, 2024.
Analysts expect IMTX's revenue for the third quarter (ending September 2024) to increase 161.1% year-over-year to $16.55 million. For the fiscal year 2024, the company's revenue is expected to grow 35.6% year-over-year to $79.48 million. Also, the company has topped the consensus EPS estimates in all of the trailing four quarters.
IMTX's shares have gained 36.3% over the past nine months to close the last trading session at $11.49. Wall Street analysts expect the stock to hit $17.33 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/imtx/forecast">upside of 50.8%</a>.
IMTX's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value. Within the Biotech industry, IMTX is ranked #76 among the 341 stocks.
In addition to the POWR Ratings we've stated above, we also have IMTX ratings for Quality, Growth, Momentum, Stability, and Sentiment. Get all IMTX ratings <a href="https://stocknews.com/stock/IMTX/">here</a>.
Stock #1: Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
JAZZ identifies, develops, and commercializes pharmaceutical products for unmet medical needs internationally. The company provides Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, Enrylaz, Defitelio, and Vyxeos.
JAZZ's trailing-12-month gross profit and EBIT margins of 92.60% and 19.84% are 61.3% and 787.6% higher than the respective industry averages of 57.41% and 2.23%. Likewise, the stock's trailing-12-month levered FCF margin of 27.17% is significantly higher than the industry average of 1.30%.
During the second quarter, which ended June 30, 2024, JAZZ's total revenues increased 6.9% year-over-year to $1.02 billion. Its income from operations grew 26.5% from the year-ago value to $199.44 million. The company's non-GAAP adjusted net income and EPS came in at $364.73 million and $5.30, reflecting growth of 12.2% and 17.5% year-over-year, respectively.
Furthermore, the company's cash and cash equivalents and total assets stood at $1.35 billion and $11.36 billion as of June 30, 2024.
According to the company's full year 2024 financial guidance, JAZZ expects its revenues between $4 billion and $4.10 billion. Its net income is expected to be $1.27 billion - $1.35 billion and $19.20 - $20.30 per share.
Street expects JAZZ's revenue for the third quarter (ending September 2024) to increase 6.6% year-over-year to $1.04 billion. Its EPS for the same quarter is expected to grow 14.2% year-over-year to $5.53. Also, the company has topped the consensus revenue estimates in three of the four trailing quarters.
JAZZ's stock has soared 3.1% over the past month to close the last trading session at $114.29. Wall Street analysts expect the stock to hit $173.76 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/jazz/forecast">upside of 52%</a>.
JAZZ's POWR Ratings reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
JAZZ has an A grade for Value and Growth. It also has a B grade for Sentiment, and Quality. It is ranked #4 among the 341 stocks in the same industry.
<a href="https://stocknews.com/stock/JAZZ/">Click here</a> to access additional JAZZ ratings for Stability and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
JAZZ shares were trading at $114.61 per share on Tuesday afternoon, up $0.32 (+0.28%). Year-to-date, JAZZ has declined -6.82%, versus a 18.91% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jazz-imtx-pyxs-3-oncology-stocks-with-major-upside/>3 Oncology Stocks With Major Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Oncology Stocks With Major Upside

Moment Of Truth Approaches For Pyxis Oncology

In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with a price targe...

Pyxis Oncology (PYXS) Gets a Buy from RBC Capital

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on PYXS stock, giving a Buy rating on September 19. Jeffrey La Rosa ha...

Pyxis Oncology's PYX-201 Earns 'Buy' Rating on Promising ADC Program Developments

Analyst Jeffrey La Rosa of Leerink Partners maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with a price target of $12.00. Jeff...

Optimistic Buy Recommendation for Pyxis Oncology: Promising Prospects for Lead Drug PYX-201

"At Pyxis Oncology (PYXS), our team has been working diligently to deliver preliminary data from our first-in-patient clinical trial of PYX-201. In...

Pyxis Oncology reports Q3 EPS (35c), consensus (31c)

The Company ended the third quarter of 2024 with $146.3 million in cash, cash equivalents, restricted cash, and short-term investments, which is ex...

Pyxis Oncology sees cash runway into 2H26

Pyxis Oncology GAAP EPS of -$0.35 misses by $0.04

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating on November 7. Sam Slutsky's rating is b...

Positive Outlook for Pyxis Oncology: Strong Clinical Programs and Financial Stability Justify Buy Rating

IMTX

JAZZ

PYXS

Earnings

Press Releases

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Health Care

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

Comments

Pyxis Oncology

Actualités

Dernières nouvelles pour Pyxis Oncology (NASDAQ:PYXS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL